These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 32172272)

  • 1. Biosimilar pegfilgrastim and adherence to guidelines for chemotherapy-induced neutropenia and infections in cancer patients.
    Danova M; Antonuzzo A; Spandonaro F; Pronzato P
    Infez Med; 2020 Mar; 28(1):127-129. PubMed ID: 32172272
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of biosimilar filgrastim vs. original granulocyte colony-stimulating factors in febrile neutropenia prevention in breast cancer patients.
    Puértolas I; Frutos Pérez-Surio A; Alcácera MA; Andrés R; Salvador MDT
    Eur J Clin Pharmacol; 2018 Mar; 74(3):315-321. PubMed ID: 29152672
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparison of eflapegrastim to pegfilgrastim in the management of chemotherapy-induced neutropenia in patients with early-stage breast cancer undergoing cytotoxic chemotherapy (RECOVER): A Phase 3 study.
    Cobb PW; Moon YW; Mezei K; Láng I; Bhat G; Chawla S; Hasal SJ; Schwartzberg LS
    Cancer Med; 2020 Sep; 9(17):6234-6243. PubMed ID: 32687266
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overuse and underuse of pegfilgrastim for primary prophylaxis of febrile neutropenia.
    Zullo AR; Lou U; Cabral SE; Huynh J; Berard-Collins CM
    J Oncol Pharm Pract; 2019 Sep; 25(6):1357-1365. PubMed ID: 30124123
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Granulocyte colony-stimulating factors used in clinical practice: PoloNord Registry-Based Cohort Italian Study.
    Fagnani D; Isa L; Verga MF; Nova P; Casartelli C; Filipazzi V; Danova M; Farina G; Pugliese P; Fava S; Bertolini A; Cimminiello C; Boracchi P; Marano G; Panzarino C;
    Tumori; 2014; 100(5):491-8. PubMed ID: 25343541
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pegfilgrastim: a recent advance in the prophylaxis of chemotherapy-induced neutropenia.
    Waladkhani AR
    Eur J Cancer Care (Engl); 2004 Sep; 13(4):371-9. PubMed ID: 15305906
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Myelodysplastic syndrome and acute myeloid leukemia after receipt of granulocyte colony-stimulating factors in older patients with non-Hodgkin lymphoma.
    Calip GS; Moran KM; Sweiss KI; Patel PR; Wu Z; Adimadhyam S; Lee TA; Ko NY; Quigley JG; Chiu BC
    Cancer; 2019 Apr; 125(7):1143-1154. PubMed ID: 30548485
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neulasta (pegfilgrastim): a once-per-cycle option for the management of chemotherapy-induced neutropenia.
    Biganzoli L; Untch M; Skacel T; Pico JL
    Semin Oncol; 2004 Jun; 31(3 Suppl 8):27-34. PubMed ID: 15181606
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biosimilar Pegfilgrastim: Improving Access and Optimising Practice to Supportive Care that Enables Cure.
    Cornes P; Gascon P; Vulto AG; Aapro M
    BioDrugs; 2020 Jun; 34(3):255-263. PubMed ID: 32232676
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Granulocyte colony-stimulating factors in the management of chemotherapy-induced neutropenia: evidence based review.
    Bhana N
    Curr Opin Oncol; 2007 Jul; 19(4):328-35. PubMed ID: 17545795
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The clinical use of granulocyte-colony stimulating factor.
    Shah J; Welsh SJ
    Br J Hosp Med (Lond); 2014 Feb; 75(2):C29-32. PubMed ID: 24521833
    [No Abstract]   [Full Text] [Related]  

  • 12. Prophylaxis of febrile neutropenia with colony-stimulating factors: the first 25 years.
    Edelsberg J; Weycker D; Bensink M; Bowers C; Lyman GH
    Curr Med Res Opin; 2020 Mar; 36(3):483-495. PubMed ID: 31834830
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative effectiveness of pegfilgrastim biosimilars vs originator for prevention of febrile neutropenia: A retrospective cohort study.
    Wang CY; Vouri SM; Park H; Heldermon CD; Brown JD
    J Manag Care Spec Pharm; 2023 Feb; 29(2):119-127. PubMed ID: 36705287
    [No Abstract]   [Full Text] [Related]  

  • 14. Systematic Review and Meta-analysis of Short- versus Long-Acting Granulocyte Colony-Stimulating Factors for Reduction of Chemotherapy-Induced Febrile Neutropenia.
    Cornes P; Gascon P; Chan S; Hameed K; Mitchell CR; Field P; Latymer M; Arantes LH
    Adv Ther; 2018 Nov; 35(11):1816-1829. PubMed ID: 30298233
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Antineoplastic drug-induced neutropenia: use of granulocyte colony stimulating factors].
    Carrato A; Guillén-Ponce C; Grande-Pulido E
    Farm Hosp; 2010 Mar; 34 Suppl 1():8-11. PubMed ID: 20920851
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pegfilgrastim for the prevention of chemotherapy-induced febrile neutropenia in patients with solid tumors.
    Lambertini M; Ferreira AR; Del Mastro L; Danesi R; Pronzato P
    Expert Opin Biol Ther; 2015; 15(12):1799-817. PubMed ID: 26488491
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An analysis of current neutropenia therapies, including pegfilgrastim.
    Gabrilove JL
    Clin Cornerstone; 2006; 8 Suppl 5():S19-28. PubMed ID: 17379160
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Not Available].
    Aktuelle Urol; 2016 May; 47(3):189. PubMed ID: 27271443
    [No Abstract]   [Full Text] [Related]  

  • 19. Pegfilgrastim in primary prophylaxis of febrile neutropenia during chemotherapy of relapsed and refractory multiple myeloma: a real-life experience.
    Cerchione C; Catalano L; Pareto AE; Picardi M; Pane F
    Support Care Cancer; 2015 Feb; 23(2):301-2. PubMed ID: 25341551
    [No Abstract]   [Full Text] [Related]  

  • 20. Appropriateness of granulocyte colony-stimulating factor use in patients receiving chemotherapy by febrile neutropenia risk level.
    Baig H; Somlo B; Eisen M; Stryker S; Bensink M; Morrow PK
    J Oncol Pharm Pract; 2019 Oct; 25(7):1576-1585. PubMed ID: 30200842
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.